❌

Normal view

  • ✇Latest Science News -- ScienceDaily
  • Scientists discover brain switches that clear Alzheimer’s plaques
    Researchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimer’s disease. By stimulating these receptors in mice, scientists increased levels of a natural amyloid-breaking enzyme, reduced buildup in the brain, and improved memory-related behavior. Because these receptors are common drug targets, the findings could open the door to affordable pill-based treatments with fewer side effects.
     

Scientists discover brain switches that clear Alzheimer’s plaques

17 February 2026 at 18:30
Researchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimer’s disease. By stimulating these receptors in mice, scientists increased levels of a natural amyloid-breaking enzyme, reduced buildup in the brain, and improved memory-related behavior. Because these receptors are common drug targets, the findings could open the door to affordable pill-based treatments with fewer side effects.

Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation

arXiv:2602.15019v1 Announce Type: new Abstract: Bio-pharmaceutical innovation has shifted: many new drug assets now originate outside the United States and are disclosed primarily via regional, non-English channels. Recent data suggests >85% of patent filings originate outside the U.S., with China accounting for nearly half of the global total; a growing share of scholarly output is also non-U.S. Industry estimates put China at ~30% of global drug development, spanning 1,200+ novel candidates. In this high-stakes environment, failing to surface "under-the-radar" assets creates multi-billion-dollar risk for investors and business development teams, making asset scouting a coverage-critical competition where speed and completeness drive value. Yet today's Deep Research AI agents still lag human experts in achieving high-recall discovery across heterogeneous, multilingual sources without hallucinations. We propose a benchmarking methodology for drug asset scouting and a tuned, tree-based self-learning Bioptic Agent aimed at complete, non-hallucinated scouting. We construct a challenging completeness benchmark using a multilingual multi-agent pipeline: complex user queries paired with ground-truth assets that are largely outside U.S.-centric radar. To reflect real deal complexity, we collected screening queries from expert investors, BD, and VC professionals and used them as priors to conditionally generate benchmark queries. For grading, we use LLM-as-judge evaluation calibrated to expert opinions. We compare Bioptic Agent against Claude Opus 4.6, OpenAI GPT-5.2 Pro, Perplexity Deep Research, Gemini 3 Pro + Deep Research, and Exa Websets. Bioptic Agent achieves 79.7% F1 versus 56.2% (Claude Opus 4.6), 50.6% (Gemini 3 Pro + Deep Research), 46.6% (GPT-5.2 Pro), 44.2% (Perplexity Deep Research), and 26.9% (Exa Websets). Performance improves steeply with additional compute, supporting the view that more compute yields better results.

MedScope: Incentivizing "Think with Videos" for Clinical Reasoning via Coarse-to-Fine Tool Calling

arXiv:2602.13332v1 Announce Type: cross Abstract: Long-form clinical videos are central to visual evidence-based decision-making, with growing importance for applications such as surgical robotics and related settings. However, current multimodal large language models typically process videos with passive sampling or weakly grounded inspection, which limits their ability to iteratively locate, verify, and justify predictions with temporally targeted evidence. To close this gap, we propose MedScope, a tool-using clinical video reasoning model that performs coarse-to-fine evidence seeking over long-form procedures. By interleaving intermediate reasoning with targeted tool calls and verification on retrieved observations, MedScope produces more accurate and trustworthy predictions that are explicitly grounded in temporally localized visual evidence. To address the lack of high-fidelity supervision, we build ClinVideoSuite, an evidence-centric, fine-grained clinical video suite. We then optimize MedScope with Grounding-Aware Group Relative Policy Optimization (GA-GRPO), which directly reinforces tool use with grounding-aligned rewards and evidence-weighted advantages. On full and fine-grained video understanding benchmarks, MedScope achieves state-of-the-art performance in both in-domain and out-of-domain evaluations. Our approach illuminates a path toward medical AI agents that can genuinely "think with videos" through tool-integrated reasoning. We will release our code, models, and data.

Large study finds no link between mRNA COVID vaccine in pregnancy and autism

15 February 2026 at 22:51
Researchers tracked more than 400 toddlers to see whether mRNA COVID-19 vaccination during or just before pregnancy was linked to autism or developmental delays. After detailed assessments of speech, motor skills, behavior, and social development, they found no meaningful differences between vaccinated and unvaccinated groups. Experts say the results provide strong reassurance about vaccine safety in pregnancy.
  • ✇AI News
  • AI forecasting model targets healthcare resource efficiency Ryan Daws
    An operational AI forecasting model developed by Hertfordshire University researchers aims to improve resource efficiency within healthcare. Public sector organisations often hold large archives of historical data that do not inform forward-looking decisions. A partnership between the University of Hertfordshire and regional NHS health bodies addresses this issue by applying machine learning to operational planning. The project analyses healthcare demand to assist managers with decisions rega
     

AI forecasting model targets healthcare resource efficiency

14 February 2026 at 00:07

An operational AI forecasting model developed by Hertfordshire University researchers aims to improve resource efficiency within healthcare.

Public sector organisations often hold large archives of historical data that do not inform forward-looking decisions. A partnership between the University of Hertfordshire and regional NHS health bodies addresses this issue by applying machine learning to operational planning. The project analyses healthcare demand to assist managers with decisions regarding staffing, patient care, and resources.

Most AI initiatives in healthcare focus on individual diagnostics or patient-level interventions. The project team notes that this tool targets system-wide operational management instead. This distinction matters for leaders evaluating where to deploy automated analysis within their own infrastructure.

The model uses five years of historical data to build its projections. It integrates metrics such as admissions, treatments, re-admissions, bed capacity, and infrastructure pressures. The system also accounts for workforce availability and local demographic factors including age, gender, ethnicity, and deprivation.

Iosif Mporas, Professor of Signal Processing and Machine Learning at the University of Hertfordshire, leads the project. The team includes two full-time postdoctoral researchers and will continue development through 2026.

“By working together with the NHS, we are creating tools that can forecast what will happen if no action is taken and quantify the impact of a changing regional demographic on NHS resources,” said Professor Mporas.

Using AI for forecasting in healthcare operations

The model produces forecasts showing how healthcare demand is likely to change. It models the impact of these changes in the short-, medium-, and long-term. This capability allows leadership to move beyond reactive management.

Charlotte Mullins, Strategic Programme Manager for NHS Herts and West Essex, commented: “The strategic modelling of demand can affect everything from patient outcomes including the increased number of patients living with chronic conditions.

“Used properly, this tool could enable NHS leaders to take more proactive decisions and enable delivery of the 10-year plan articulated within the Central East Integrated Care Board as our strategy document.” 

The University of Hertfordshire Integrated Care System partnership funds the work, which began last year. Testing of the AI model tailored for healthcare operations is currently underway in hospital settings. The project roadmap includes extending the model to community services and care homes.

This expansion aligns with structural changes in the region. The Hertfordshire and West Essex Integrated Care Board serves 1.6 million residents and is preparing to merge with two neighbouring boards. This merger will create the Central East Integrated Care Board. The next phase of development will incorporate data from this wider population to improve the predictive accuracy of the model.

The initiative demonstrates how legacy data can drive cost efficiencies and shows that predictive models can inform “do nothing” assessments and resource allocation in complex service environments like the NHS. The project highlights the necessity of integrating varied data sources – from workforce numbers to population health trends – to create a unified view for decision-making.

See also: Agentic AI in healthcare: How Life Sciences marketing could achieve $450B in value by 2028

Banner for AI & Big Data Expo by TechEx events.

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events including the Cyber Security & Cloud Expo. Click here for more information.

AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.

The post AI forecasting model targets healthcare resource efficiency appeared first on AI News.

Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas

Int J Mol Sci. 2026 Feb 6;27(3):1597. doi: 10.3390/ijms27031597.

ABSTRACT

Ampullary carcinoma (AC) is a rare gastrointestinal malignancy with dual intestinal and pancreatobiliary differentiation, complicating diagnosis, staging, and treatment. This review synthesizes current epidemiology, pathology, and multi-omic data to outline a pragmatic care pathway: lineage-first at presentation, mutation-fast at progression. Histology remains the primary classifier: the intestinal subtype generally aligns with colorectal regimens, whereas pancreatobiliary and mixed subtypes favor pancreaticobiliary therapy. In selected fit patients, modified FOLFIRINOX may address mixed phenotypes. Next-generation sequencing adds precision by identifying therapeutically relevant alterations, including ERBB2/HER2 amplifications, MSI-high/dMMR, BRAF V600E, and rare NTRK or RET fusions, while KRAS mutations are enriched in pancreatobiliary tumors. We recommend early application of a rapid-core panel (KRAS/BRAF, MSI/dMMR, ERBB2/HER2, RNA-based fusions) to capture high-impact targets, followed by comprehensive profiling at first progression. Liquid biopsy, plasma circulating tumor DNA (ctDNA), or bile-derived DNA may complement tissue and help identify the dominant lineage. Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.

PMID:41684016 | PMC:PMC12897727 | DOI:10.3390/ijms27031597

❌